609 Health launched Zyprexa Relprevv at Eli Lilly.

609 combines experience launching world leading cardiometabolic therapies with deep expertise in EHRs, digital health, software development, gross to net, 340B, and direct to patient strategy to help manufacturers connect strategy with real world execution. After innovating for nearly a decade inside Eli Lilly during one of the most significant growth cycles in its history, I saw firsthand where strategy breaks down in the real world. At 609 Health, we build digital infrastructure for modern market access—applying engineering discipline to connect strategy, workflows, and data across HCPs, health systems, and direct-to-patient and direct-to-employer channels. Our work focuses on the invisible mechanics that determine how therapies actually reach patients. Through a Design → Prepare → Execute → Understand → Prove operating model, we help organizations: • Design channel and access strategy across HCP, HCO, and DTP models • Prepare clinical systems and workflows for real-world execution • Execute through demand realization, decisioning, and workflow enablement • Understand revenue exposure across 340B, G2N, and access pathways • Prove outcomes through evidence, measurement, and narrative We combine strategic advisory with active product development, including: • AccessNexus.ai — illuminating the economic pathways that determine drug access and payer coverage • DealForge.ai — scenario-based pricing and gross-to-net modeling for payer strategy and financial exposure • OutcomeFoundry — analytics infrastructure measuring real-world performance of healthcare interventions We help organizations unlock access, reduce revenue leakage, and deliver measurable real-world impact. The future of healthcare won’t just be built with new therapies—it will be built with better systems.